President Trump has promoted a few different drugs as effective remedies against the novel coronavirus in recent days, but demand for one of them has become so overwhelming that its manufacturer has temporarily shut down its emergency access program to build a broader one, The New York Times reports.
Gilead, which produces remdesivir, a drug that's being studied in large-scale clinical trials across the globe and is currently administered in certain coronavirus cases, said it can no longer grant compassionate use requests because it can't keep up with the number coming in. The company said its emergency access program was limited and never intended for a pandemic, but now that the world is facing one, Gilead intends to set up a broader access program to help more people. "This approach will both accelerate access to remdesivir for severely ill patients and enable the collection of data from all participating patients," the company said in a statement.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Today's political cartoons - November 24, 2024Cartoons Sunday's cartoons - taped bananas, flying monkeys, and more
-
The Spanish cop, 20 million euros and 13 tonnes of cocaineIn the Spotlight Óscar Sánchez Gil, Chief Inspector of Spain's Economic and Tax Crimes Unit, has been arrested for drug trafficking
-
5 hilarious cartoons about the rise and fall of Matt GaetzCartoons Artists take on age brackets, backbiting, and more
-
ACA opens 2025 enrollment, enters 2024 raceSpeed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
-
McDonald's sued over E. coli linked to burgerSpeed Read The outbreak has sickened at least 49 people in 10 states and left one dead
-
Long Covid: study shows damage to brain's 'control centre'The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
-
FDA OKs new Covid vaccine, available soonSpeed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
-
Mpox: how dangerous is new health emergency?Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
-
What is POTS and why is it more common now?The explainer The condition affecting young women
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry reportThe Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
-
Should masks be here to stay?Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
